Search - tctmd.com

Displaying 381 - 400 of 722

Sort: Relevancy | Date

Presentation Fellows 2016

How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy

Presenter: Roxana Mehran

April 15, 2016

Presentation Fellows 2016

Antiplatelet Therapy for the Interventionalist

Presenter: Roxana Mehran

April 15, 2016

Presentation JIM 2016

Intravenous P2Y12 Receptor Inhibitors With Powerful Oral Antiplatelets Are The New Best Option!

Presenter: Roxana Mehran

February 11, 2016

Presentation JIM 2016

Self- Apposing Stents in STEMI:The Stentys Experience

Presenter: Roxana Mehran

February 10, 2016

News Daily News

Ticagrelor Loading Dose Provides Faster Platelet Inhibition Than Clopidogrel in Ad Hoc PCI

L.A. McKeown

February 09, 2016

News Daily News

Un Documento de AHA Defiende que Hay que Mejorar los Resultados de Mujeres Víctimas de IAM

Caitlin E. Cox

January 25, 2016

News Daily News

AHA 报告为改善女性急性心梗患者结局铺路

Caitlin E. Cox

January 25, 2016

News Daily News

AHA Document Builds the Case for How to Improve Outcomes for Women With Acute MI

Caitlin E. Cox

January 25, 2016

News Daily News

导管室并发症：新的分析精准确定了 ACS 患者术中血栓事件的事件率及风险

Shelley Wood

January 21, 2016

News Daily News

Complicaciones en el Laboratorio de Cateterización: Un Nuevo Análisis Define el Índice y Riesgos de los Episodios Trombóticos Intraoperatorios en el Manejo del SCA

Shelley Wood

January 21, 2016

News Daily News

Cath-Lab Complications: New Analysis Pinpoints Rate and Risks of Intraprocedural Thrombotic Events in ACS

Shelley Wood

January 21, 2016

News Daily News

Symptom Duration May Be More Important Than D2B for STEMI, HORIZONS-AMI Substudy Suggests

Yael L. Maxwell

January 05, 2016

News Daily News

La Duración de los Síntomas Podría ser Más Importante que el Tiempo Puerta-Balón en el Manejo de Los Cuadros de STEMI, según un Subestudio del HORIZONS-AMI

Yael L. Maxwell

January 05, 2016

News Daily News

HORIZONS-AMI 亚组研究表明，STEMI 患者的症状持续时间可能比 D2B 更重要

Yael L. Maxwell

January 05, 2016

News Industry News

One-Year Outcomes From the COMBO REMEDEE All-Comers Registry Presented at TCT 2015

October 20, 2015

$Bivalirudin Versus Unfractionated Heparin Analysis: What Is Really Best in Which Patients?$

Presentation TCT 2015

Bivalirudin Versus Unfractionated Heparin Analysis: What Is Really Best in Which Patients?

Presenter: Carlo Briguori, Roxana Mehran, Carey D. Kimmelstiel

October 15, 2015

Presentation TCT 2015

MATRIX Trial Recap: Interaction Between Access Site and Antithrombin Choice in ACS

Presenter: Carlo Briguori, Roxana Mehran

October 15, 2015

Presentation TCT 2015

The REG1 Anticoagulation System: Lessons From Factor IX Inhibitor Using RNA Aptamer Technology

Presenter: Carlo Briguori, Roxana Mehran

October 15, 2015

Presentation TCT 2015

Contrast Nephropathy Clinical Trial Updates (AVERT, RenalGuard, Preserve, and Others)

Presenter: Somjot S. Brar, Richard Solomon, Roxana Mehran

October 15, 2015

Presentation TCT 2015

The PIONEER Trial (Rivaroxaban in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

Presenter: Pascal Vranckx, Roxana Mehran

October 14, 2015

Advertisement

How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy

Antiplatelet Therapy for the Interventionalist

Intravenous P2Y12 Receptor Inhibitors With Powerful Oral Antiplatelets Are The New Best Option!

Self- Apposing Stents in STEMI:The Stentys Experience

Ticagrelor Loading Dose Provides Faster Platelet Inhibition Than Clopidogrel in Ad Hoc PCI

Un Documento de AHA Defiende que Hay que Mejorar los Resultados de Mujeres Víctimas de IAM

AHA 报告为改善女性急性心梗患者结局铺路

AHA Document Builds the Case for How to Improve Outcomes for Women With Acute MI

导管室并发症：新的分析精准确定了 ACS 患者术中血栓事件的事件率及风险

Complicaciones en el Laboratorio de Cateterización: Un Nuevo Análisis Define el Índice y Riesgos de los Episodios Trombóticos Intraoperatorios en el Manejo del SCA

Cath-Lab Complications: New Analysis Pinpoints Rate and Risks of Intraprocedural Thrombotic Events in ACS

Symptom Duration May Be More Important Than D2B for STEMI, HORIZONS-AMI Substudy Suggests

La Duración de los Síntomas Podría ser Más Importante que el Tiempo Puerta-Balón en el Manejo de Los Cuadros de STEMI, según un Subestudio del HORIZONS-AMI

HORIZONS-AMI 亚组研究表明，STEMI 患者的症状持续时间可能比 D2B 更重要

One-Year Outcomes From the COMBO REMEDEE All-Comers Registry Presented at TCT 2015

Bivalirudin Versus Unfractionated Heparin Analysis: What Is Really Best in Which Patients?

MATRIX Trial Recap: Interaction Between Access Site and Antithrombin Choice in ACS

The REG1 Anticoagulation System: Lessons From Factor IX Inhibitor Using RNA Aptamer Technology

Contrast Nephropathy Clinical Trial Updates (AVERT, RenalGuard, Preserve, and Others)

The PIONEER Trial (Rivaroxaban in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content